JSLL Jeena Sikho Q2 FY25 results (Jul–Sep 2024) and concall
Jeena Sikho Lifecare Limited reported robust H1 FY25 results, driven by strong growth in hospital services and product sales. The company achieved a 36% YoY revenue increase to INR214 crores and a 47% YoY PAT growth to INR46.88 crores. Strategic expansion in bed capacity, a focus on patient-centric Ayurvedic treatments, and an aggressive entry into the OTC medicine market are key drivers for future growth, alongside international expansion plans.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 114 |
| EBITDA | 40 |
| Net profit | 27 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
